Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2025
0mins
Should l Buy PHAT?
Source: Newsfilter
New Appointment at Phathom Pharmaceuticals: Anne Marie Cook has been appointed as Chief Legal Officer and Corporate Secretary of Phathom Pharmaceuticals, bringing extensive experience from her previous roles in various pharmaceutical companies.
Company's Focus and Future Goals: Phathom Pharmaceuticals aims to redefine care standards for gastrointestinal diseases, leveraging Cook's expertise to enhance corporate strategy and drive the company's growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHAT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHAT
Wall Street analysts forecast PHAT stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 11.110
Low
16.00
Averages
25.40
High
29.00
Current: 11.110
Low
16.00
Averages
25.40
High
29.00
About PHAT
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Emerging Trends in H. pylori Infection Market
- Market Size Growth: The H. pylori infection market is projected to reach $270 million by 2025, with the U.S. accounting for 85% of this market, indicating strong demand for new therapies and significant future market potential.
- Emerging Therapy Development: New therapies like Rifasutenizol from TenNor Therapeutics show over 90% eradication rates in clinical trials, potentially becoming the first innovative therapy for H. pylori, enhancing treatment efficacy and reducing resistance risks.
- Optimized Treatment Strategies: The incorporation of bismuth into triple therapy has increased eradication rates by 30-40%, reflecting effective strategies against antibiotic-resistant H. pylori and driving improvements in treatment standards.
- Adult-Pediatric Treatment Differences: Adult guidelines emphasize widespread eradication to lower gastric cancer risks, while pediatric recommendations require more cautious, targeted strategies, creating opportunities for personalized prevention and intervention programs.
See More
Phathom Pharmaceuticals Q4 2025 Earnings Call Highlights
- Strong Financial Performance: Phathom Pharmaceuticals reported Q4 2025 net revenues of $57.6 million, reflecting a 16% sequential growth, indicating significant improvements in sales and operational efficiency, with 2026 revenue guidance projected between $320 million and $345 million, showcasing robust market demand and growth potential.
- Capital Structure Optimization: The company successfully completed a $130 million equity offering and renegotiated debt terms, reducing the loan interest rate from 12% to 9.85%, which will significantly alleviate future financial burdens and enhance the company's financial flexibility and sustainability.
- Significant Prescription Growth: To date, total prescriptions for VOQUEZNA have exceeded 1.1 million, with Q4 alone reaching 273,000 prescriptions, a 21% quarter-over-quarter increase, indicating the company's increasing market penetration in the gastrointestinal sector and further solidifying its market position.
- Optimistic Future Outlook: Management anticipates achieving operational profitability in 2026 and cash flow positivity by 2027, emphasizing the successful execution of its GI strategy and the effectiveness of its sales team, laying a solid foundation for continued growth in the future.
See More
Phathom Pharmaceuticals Set to Announce Q4 Earnings
- Earnings Announcement Date: Phathom Pharmaceuticals is set to release its Q4 2023 earnings on February 26 before market open, with a consensus EPS estimate of -$0.19, reflecting a significant year-over-year improvement of 75.9%, indicating potential recovery in profitability.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $57.44 million, representing a robust year-over-year increase of 93.4%, which underscores Phathom's strong market demand and sales performance, potentially enhancing its attractiveness for future investments.
- Performance Beat Record: Over the past year, Phathom has beaten EPS estimates 50% of the time and revenue estimates 75% of the time, demonstrating the company's reliability in financial forecasting and adaptability to market conditions.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 1 downward revision, while revenue estimates have experienced 6 upward revisions with no downward adjustments, indicating growing analyst confidence in Phathom's future performance.
See More
Phathom Pharmaceuticals Sees Q4 Sales of $57-58M, Prices $130M Public Offering
- Sales Forecast Increase: Phathom Pharmaceuticals anticipates Q4 2025 sales between $57 million and $58 million, exceeding the consensus estimate of $56.16 million, indicating strong market competitiveness and growing product demand.
- Annual Revenue Guidance Update: The company has raised its full-year 2025 revenue guidance to approximately $174.5 million to $175.5 million from the previous $170 million to $175 million, reflecting an optimistic outlook for future performance.
- Prescription Milestone: Voquezna has surpassed one million prescriptions dispensed in the U.S. since its launch, demonstrating strong market acceptance and clinical demand for the treatment of gastroesophageal reflux disease (GERD).
- Financing Plan: Phathom Pharmaceuticals successfully priced its underwritten public offering of 6.875 million shares at $16 per share, expected to raise approximately $130 million for general corporate purposes, including working capital and R&D expenses, showcasing the company's financial support capability for future growth.
See More
Northrop Grumman Shares Rise 6.84% Following Military Budget Proposal
- Stock Surge: Northrop Grumman's shares rose 6.84% following President Trump's proposal to increase the 2027 military budget from $1 trillion to $1.5 trillion, indicating market optimism about defense spending that could drive future performance growth.
- Market Reaction: Despite a generally poor market performance, Northrop Grumman's stock increased, reflecting investor confidence in the defense sector, particularly amid current geopolitical tensions where defense spending may become a key economic growth driver.
- Industry Trends: With the anticipated increase in defense budgets, Northrop Grumman is likely to secure more government contracts, enhancing its market share and profitability, thereby solidifying its leadership position in the defense industry.
- Investor Focus: The market remains highly attentive to upcoming economic data, especially initial jobless claims and trade deficit figures, which could influence overall market sentiment and investment decisions.
See More
AZZ Inc Reports Q3 Earnings Beat, Shares Rise 2.1%
- Earnings Beat: AZZ Inc reported adjusted earnings of $1.52 per share for Q3, surpassing market expectations of $1.47, indicating sustained profitability that may attract more investor interest.
- Sales Growth: The company achieved sales of $425.746 million, exceeding expectations of $418.164 million, demonstrating strong market demand and further solidifying its position in the industry.
- Stock Price Surge: In pre-market trading, AZZ Inc shares rose 2.1% to $112.09, reflecting a positive market reaction to its earnings report, which could boost investor confidence in subsequent trading days.
- Optimistic Market Outlook: With improved performance, AZZ Inc is poised to continue attracting investment and enhancing its competitive edge, particularly in the context of the current economic recovery.
See More
Emerging Trends in H. pylori Infection Market
- Market Size Growth: The H. pylori infection market is projected to reach $270 million by 2025, with the U.S. accounting for 85% of this market, indicating strong demand for new therapies and significant future market potential.
- Emerging Therapy Development: New therapies like Rifasutenizol from TenNor Therapeutics show over 90% eradication rates in clinical trials, potentially becoming the first innovative therapy for H. pylori, enhancing treatment efficacy and reducing resistance risks.
- Optimized Treatment Strategies: The incorporation of bismuth into triple therapy has increased eradication rates by 30-40%, reflecting effective strategies against antibiotic-resistant H. pylori and driving improvements in treatment standards.
- Adult-Pediatric Treatment Differences: Adult guidelines emphasize widespread eradication to lower gastric cancer risks, while pediatric recommendations require more cautious, targeted strategies, creating opportunities for personalized prevention and intervention programs.
See More
Phathom Pharmaceuticals Q4 2025 Earnings Call Highlights
- Strong Financial Performance: Phathom Pharmaceuticals reported Q4 2025 net revenues of $57.6 million, reflecting a 16% sequential growth, indicating significant improvements in sales and operational efficiency, with 2026 revenue guidance projected between $320 million and $345 million, showcasing robust market demand and growth potential.
- Capital Structure Optimization: The company successfully completed a $130 million equity offering and renegotiated debt terms, reducing the loan interest rate from 12% to 9.85%, which will significantly alleviate future financial burdens and enhance the company's financial flexibility and sustainability.
- Significant Prescription Growth: To date, total prescriptions for VOQUEZNA have exceeded 1.1 million, with Q4 alone reaching 273,000 prescriptions, a 21% quarter-over-quarter increase, indicating the company's increasing market penetration in the gastrointestinal sector and further solidifying its market position.
- Optimistic Future Outlook: Management anticipates achieving operational profitability in 2026 and cash flow positivity by 2027, emphasizing the successful execution of its GI strategy and the effectiveness of its sales team, laying a solid foundation for continued growth in the future.
See More
Phathom Pharmaceuticals Set to Announce Q4 Earnings
- Earnings Announcement Date: Phathom Pharmaceuticals is set to release its Q4 2023 earnings on February 26 before market open, with a consensus EPS estimate of -$0.19, reflecting a significant year-over-year improvement of 75.9%, indicating potential recovery in profitability.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $57.44 million, representing a robust year-over-year increase of 93.4%, which underscores Phathom's strong market demand and sales performance, potentially enhancing its attractiveness for future investments.
- Performance Beat Record: Over the past year, Phathom has beaten EPS estimates 50% of the time and revenue estimates 75% of the time, demonstrating the company's reliability in financial forecasting and adaptability to market conditions.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 1 downward revision, while revenue estimates have experienced 6 upward revisions with no downward adjustments, indicating growing analyst confidence in Phathom's future performance.
See More
Phathom Pharmaceuticals Sees Q4 Sales of $57-58M, Prices $130M Public Offering
- Sales Forecast Increase: Phathom Pharmaceuticals anticipates Q4 2025 sales between $57 million and $58 million, exceeding the consensus estimate of $56.16 million, indicating strong market competitiveness and growing product demand.
- Annual Revenue Guidance Update: The company has raised its full-year 2025 revenue guidance to approximately $174.5 million to $175.5 million from the previous $170 million to $175 million, reflecting an optimistic outlook for future performance.
- Prescription Milestone: Voquezna has surpassed one million prescriptions dispensed in the U.S. since its launch, demonstrating strong market acceptance and clinical demand for the treatment of gastroesophageal reflux disease (GERD).
- Financing Plan: Phathom Pharmaceuticals successfully priced its underwritten public offering of 6.875 million shares at $16 per share, expected to raise approximately $130 million for general corporate purposes, including working capital and R&D expenses, showcasing the company's financial support capability for future growth.
See More
Northrop Grumman Shares Rise 6.84% Following Military Budget Proposal
- Stock Surge: Northrop Grumman's shares rose 6.84% following President Trump's proposal to increase the 2027 military budget from $1 trillion to $1.5 trillion, indicating market optimism about defense spending that could drive future performance growth.
- Market Reaction: Despite a generally poor market performance, Northrop Grumman's stock increased, reflecting investor confidence in the defense sector, particularly amid current geopolitical tensions where defense spending may become a key economic growth driver.
- Industry Trends: With the anticipated increase in defense budgets, Northrop Grumman is likely to secure more government contracts, enhancing its market share and profitability, thereby solidifying its leadership position in the defense industry.
- Investor Focus: The market remains highly attentive to upcoming economic data, especially initial jobless claims and trade deficit figures, which could influence overall market sentiment and investment decisions.
See More
AZZ Inc Reports Q3 Earnings Beat, Shares Rise 2.1%
- Earnings Beat: AZZ Inc reported adjusted earnings of $1.52 per share for Q3, surpassing market expectations of $1.47, indicating sustained profitability that may attract more investor interest.
- Sales Growth: The company achieved sales of $425.746 million, exceeding expectations of $418.164 million, demonstrating strong market demand and further solidifying its position in the industry.
- Stock Price Surge: In pre-market trading, AZZ Inc shares rose 2.1% to $112.09, reflecting a positive market reaction to its earnings report, which could boost investor confidence in subsequent trading days.
- Optimistic Market Outlook: With improved performance, AZZ Inc is poised to continue attracting investment and enhancing its competitive edge, particularly in the context of the current economic recovery.
See More
